GAITHERSBURG, MD--(Marketwired - May 17, 2013) - Cytomedix, Inc. (OTCQX: CMXI), a regenerative therapies company commercializing and developing innovative platelet and adult stem cell technologies, announced today that Edward Field, the Company's Chief Operating Officer, has been invited to make a presentation on Partnering & Collaboration at the World Stem Cells & Regenerative Medicine Congress 2013, which will be held May 21-23, 2013 in London, United Kingdom.

Presentation Details

Time: Tuesday, May 21, 2013 @ 11:55am BST (6:55 am EST)

Track Title: Commercialisation through Collaboration: What Does Partnering In This Industry Actually Look Like?

Location: Victoria Park Plaza Hotel, London, UK

During the presentation, Mr. Field will highlight Cytomedix's two collaborations that are advancing clinical stage therapies.The first is a collaboration with the National Institute of Health (NIH) and the Cardiovascular Cell Therapy Research Network (CCTRN) for conduct of the PACE study, an 80 patient, double-blind, placebo-controlled clinical trial designed to look at the safety and efficacy of ALD-301 in peripheral artery disease patients diagnosed with intermittent claudication.This is the first ever randomized clinical trial to look at the benefits of autologous stem cell therapy in this indication.The second collaboration is with Duke University Medical Center, which is conducting a Phase 1 clinical study with ALD-451 in patients that have been treated for glioblastomas, which is the most aggressive form of brain cancer.This open-label study is designed to enroll up to 12 patients and is intended to demonstrate the safety and feasibility of ALD-451 when administered intravenously in patients with grade IV malignant glioma following surgery, radiation therapy and treatment with temozolomide.

About the World Stem Cells Regenerative Medicine Congress 2013The World Stem Cells & Regenerative Medicine Congress 2013 is Europe's largest and most senior conference for the stem cell research and regenerative medicine community.It is now in its 8th year. Topics covered will include streamlining clinical development, commercialising a stem cell-based therapy and exploiting alternative sources of funding. For more information please visit: http://www.terrapinn.com/2013/stemcells/index.stm.

About Cytomedix, Inc. Cytomedix, Inc. is a fully integrated regenerative medicine company commercializing and developing innovative platelet and adult stem cell separation products that enhance the body's natural healing processes. The Company's advanced autologous technologies offer clinicians a new treatment paradigm for wound and tissue repair. The Company's patient-derived PRP systems are marketed by Cytomedix in the U.S. and distributed internationally. Our commercial products include the AutoloGel System, cleared by the FDA for wound care and the Angel Whole Blood Separation System. The Company is developing novel regenerative therapies using our proprietary ALDH Bright Cell ("ALDH") technology to isolate a unique, biologically active population of a patient's own stem cells. A Phase 2 trial evaluating the use of ALDHbr for the treatment of ischemic stroke is underway. For additional information please visit http://www.cytomedix.com.

Safe Harbor Statement - Statements contained in this press release not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Cytomedix' actual results may differ materially due to a number of factors, many of which are beyond Cytomedix' ability to predict or control, including among many others, risks and uncertainties related to the Company's ability to successfully execute its Angel and AutoloGel sales strategies, to achieve AutoloGel expected reimbursement rates in 2013, to meet its stroke trial enrollment rates, the Company's ability to successfully integrate the Aldagen acquisition, the Company's ability to expand patient populations as contemplated, its ability to provide Medicare patients with access as expected, the Company's expectations of favorable future dialogue with potential strategic partners, and its ability to successfully manage contemplated clinical trials, to manage and address the capital needs, human resource, management, compliance and other challenges of a larger, more complex and integrated business enterprise, viability and effectiveness of the Company's sales approach and overall marketing strategies, commercial success or acceptance by the medical community, competitive responses, the Company's ability to raise additional capital and to continue as a going concern, and Cytomedix's ability to execute on its strategy to market the AutoloGel System as contemplated. To the extent that any statements made here are not historical, these statements are essentially forward-looking. The Company uses words and phrases such as "believes," "forecasted," "projects," "is expected," "remain confident," "will" and/or similar expressions to identify forward-looking statements in this press release. Undue reliance should not be placed on forward-looking information. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Cytomedix, Inc. Cytomedix operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Cytomedix undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason. Additional risks that could affect our future operating results are more fully described in our U.S. Securities and Exchange Commission filings, including our Annual Report for the year ended December 31, 2012, as amended to date, and other subsequent filings. These filings are available at http://www.sec.gov.

Follow this link:

Cytomedix to Present at the World Stem Cells & Regenerative Medicine Congress 2013

LOS ANGELES, CA--(Marketwired - May 17, 2013) - MMRGlobal, Inc. (OTCQB: MMRF) ("MMR"), a leading provider of Personal Health Records (PHRs) MyEsafeDepositBox storage solutions and MMRPro document management and imaging systems for healthcare professionals, today announced the addition of two new members to its Medical Board of Advisors.Dr. Cara Natterson, M.D., a Board-Certified Pediatrician, consultant and The New York Times best-selling author on child health and parenting, will assist the Company with its plans to educate parents on the importance of having a Personal Health Record for their children as well as the best ways to offer PHR products and services through pediatricians.Dr. Jeremy Fine, M.D. is a Concierge Medicine Specialist and Board-Certified in Internal Medicine. Based on his personal experience, Dr. Fine will assist the Company educating Concierge Medicine professionals on the value of ensuring that patients maintain an up-to-date PHR. The announcement was made following MMRGlobal CEO Bob Lorsch's appearance on Fox News Radio in a 30-minute interview on "The Vipp Jaswal Report."During the interview, which is available at https://www.facebook.com/#!/MMRGlobal?fref=ts, Lorsch discussed MMR's business and how efforts in Washington to encourage steering a portion of $27 billion in health IT stimulus to emerging growth companies like MMR brought him and his wife Kira to spearhead a humanitarian effort regarding the release of Dr. Shakil Afridi.

Dr. Natterson has written five books, including "Worry Proof," winner of the The Wall Street Journal's Best Health Book of the Year Award, and authored the American Girl book, "The Care & Keeping of You 2."She also updated American Girl's original "The Care & Keeping of You," which has sold over three million copies. Dr. Fine has served on the Executive Committee, Bioethics Committee and the Medical Informatics Committee at Cedars-Sinai Medical Center. He is a former Clinical Instructor of Medicine at both the UCLA and USC Schools of Medicine and was chosen by Los Angeles Magazine as one of the Best Doctors in Los Angeles.

According to Lorsch, "Dr. Natterson and Dr. Fine will make a great addition to the Company's Medical Board of Advisors, helping us educate two specialty markets on the value of PHRs. Dr. Natterson's role is to strategically introduce MyMedicalRecords to the pediatric market in an effort to make both pediatricians and parents aware of the importance of having a PHR for children at a very young age. Dr. Jeremy Fine truly exemplifies what Concierge Medicine is all about and being there for his patients whenever and wherever they need him."

Over the past several years, Dr. Fine routinely deployed MyMedicalRecords accounts to his Concierge Medicine patients as part of his Concierge Medicine protocol."As a result, Dr. Fine knows first-hand how valuable it can be in an emergency at 2 a.m. to have the ability to log in to MyMedicalRecords and access a patient's critical information regardless of where he or his patients are in the world. Consumer awareness of the importance of having a PHR is critical to the Company's business plan and there are no better professionals than Drs. Natterson and Fine to carry our message to physician colleagues, patients and parents," Lorsch added.

Working with qualified healthcare professionals, including the Company's medical advisers, MMR continues to focus on the deployment of its Personal Health Record products and services and the licensing of its patented technologies. MMRGlobal generates revenue from the sale of Personal Health Records to employers for employee benefits, direct to consumers, and patients. Through the MMR Stimulus Program, physicians and hospitals that offer MyMedicalRecords PHRs to patients can receive hundreds of thousands of dollars back from MMR as a reimbursement for the costs of maintaining medical records.

Following are brief biographies of the two new members of the Medical Board Advisors:

Dr. Jeremy Fine

Dr. Fine completed his medical training in internal medicine at Cedars-Sinai Medical Center in 2004 and was then selected to be Chief Resident. He has served on the Executive Committee, Bioethics Committee and the Medical Informatics Committee at Cedars-Sinai Medical Center. He is also a former Clinical Instructor of Medicine at both the UCLA and USC Schools of Medicine. He was chosen by Los Angeles Magazine as one of the Best Doctors in Los Angeles and has also been selected as one of California's Favorite Physicians. In 2010, he was voted Most Compassionate Doctor.

Dr. Cara Natterson

Dr. Natterson is a graduate of Harvard College and Johns Hopkins School of Medicine, trained in pediatrics at the University of California at San Francisco, and is a Board-Certified pediatrician and a Fellow of the American Academy of Pediatrics. A former partner at Tenth Street Pediatrics in Santa Monica, California, she now runs Worry Proof Consulting, the first of its kind pediatric practice that offers parents open-ended time to review everything from medical questions and biology basics to child development and parenting issues. Dr. Natterson appears on television, in print, and on the web, and is a New York Times bestselling author, having written several books on parenting and child health. Her most recent titles were published in February 2013: "The Care and Keeping of You 1: The Body Book for Younger Girls" and "The Care and Keeping of You 2: The Body Book for Older Girls." Dr. Natterson's consulting includes Fortune 500 companies seeking expert advice on child health, wellness and safety issues.

More here:

MMRGlobal Adds Concierge Medicine Specialist Jeremy Fine, M.D. and Pediatrician and New York Times Best-Selling Author ...

NEW YORK--(BUSINESS WIRE)--

GfK will deliver a major presentation about patient perspectives on personalized medicine at thePharmaceutical Business and Intelligence Research Group (PBIRG) Annual General Meeting, taking place May 19 to 22 in Naples, Florida.

Gavin Erickson, Principal Consultant at GfK Bridgehead, will lead the session, titled Shifting the Paradigm: Patient Knowledge, Attitudes, and Behaviors Hold the Key for Personalized Medicine. Erickson will review key aspects of the personalized medicine phenomenon, such as:

With hundreds of new biologic agents in development today, the coming tide of targeted therapies and companion diagnostics creates both opportunities and challenges for the industry, said Erickson. Patient-centric information can help manufacturers, clinicians, policy makers and payers understand the implications of personalized medicine, as we move away from one size fits all sales and marketing strategies.

Erickson has over 17 years of experience in the healthcare field, with deep knowledge of coding, coverage and payment for both Medicare and commercial health insurance. His fields of expertise include global health economics and reimbursement, hospital contracting and data analytics in the diagnostic, medical device and pharmaceutical, and commercial health plan space.

In addition, GfKs Sara Doran, Senior Research Director on GfKs Health team, will present a poster on GfKs Novel Approach to Navigating the Web of Complex Treatment Regimens. The poster focuses on a new specialty medicine market entrant, offering a clear understanding of fit versus adoption, how to illustrate complex regimen changes over time, and what drives adoption of one regimen over another.

Dorans 11 years of research experience include both US and global custom projects, with deep quantitative expertise. She has managed strategic and tactical research studies with physicians, patients and caregivers and has worked on an array of research methodologies.

GfK is sponsoring the PBIRG Opening Reception on May 19 at 7:00PM PBIRG conference attendees can visit the companys booths (# 27/28); in addition, GfK Bridgehead has authored a feature article on personalized medicine in the Spring 2013 PBIRG Perspective.

About GfK

GfK is one of the worlds largest research companies, with more than 12,000 experts working to discover new insights into the way people live, think and shop, in over 100 markets, every day. GfK is constantly innovating and using the latest technologies and the smartest methodologies to give its clients the clearest understanding of the most important people in the world: their customers. In 2012,GfKs sales amounted to EUR 1.51 billion.

Read more:

GfK to Share Insights on Personalized Medicine, Complex Treatment Regimens At PBIRG Annual Meeting

Alex Neff Clinical medicine assignment
FINAL ASSIGNMENT! Patient treatment video project for intro to clinical medicine. Thank you for a great semester! I enjoyed this class!

By: Alex Neff

Continue reading here:

Alex Neff Clinical medicine assignment - Video

An expert panel at the Institute of Medicine said recent studies examining links between sodium consumption and health outcomes support recommendations to lower sodium intake from the very high levels some Americans consume now -- 3,400 milligrams or more of sodium a day -- the equivalent to about 1.5 teaspoons of salt. UPI /Monika Graff

License photo

PHILADELPHIA, May 16 (UPI) -- The Institute of Medicine says studies found the value of cutting salt intake to very low levels is inconclusive, but the American Heart Association disagrees.

An expert panel at the Institute of Medicine said recent studies examining links between sodium consumption and health outcomes support recommendations to lower sodium intake from the very high levels some Americans consume now -- 3,400 milligrams or more of sodium a day or the equivalent of about 1.5 teaspoons of salt.

However, Brian Strom, George S. Pepper professor of public health and preventive medicine at the University of Pennsylvania Perelman School of Medicine, said the committee found evidence from these studies does not support reduction in sodium intake to below 2,300 mg per day.

The current Dietary Guidelines for Americans urge most people ages 14-50 to limit their sodium intake to 2,300 mg daily. Those ages 51 or older, African-Americans and people with hypertension, diabetes, or chronic kidney disease -- groups that together make up more than 50 percent of the U.S. population -- are advised to follow an even stricter limit of 1,500 mg per day.

These recommendations are based largely on a body of research that links higher sodium intakes to certain "surrogate markers" such as high blood pressure, an established risk factor for heart disease, Strom said.

"These new studies support previous findings that reducing sodium from very high intake levels to moderate levels improves health," Strom said in a statement. "But they also suggest that lowering sodium intake too much may actually increase a person's risk of some health problems."

Nancy Brown, chief executive officer of the American Heart Association, said the report was missing a critical component -- a comprehensive review of well-established evidence which links too much sodium to high blood pressure and heart disease.

The American Heart Association has meticulously reviewed scientific research and recommends that all Americans eat no more than 1,500 mg a day of sodium. Current average sodium consumption in the United States for people age 2 and up is more than 3,400 mg a day, Brown said.

Read more:

Institute of Medicine, Heart Association disagree on sodium

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Foundation Medicine, Inc., a molecular information company that brings comprehensive cancer genomic diagnostic testing and analysis to routine clinical care, today announced that 12 abstracts highlighting the companys progress in clinical cancer genome sequencing will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2013 taking place May 31-June 4, 2013 in Chicago.

As clinical adoption of our solid tumor assay, FoundationOne, continues to increase, we are generating a large body of evidence suggesting that a comprehensive genomic profile may provide clinically actionable information for many patients with cancer, said Michael J. Pellini, M.D., president and chief executive officer, Foundation Medicine. These data include novel findings across many tumor types and for many genomic targets. The 2013 ASCO meeting will be an exciting venue to share and discuss new discoveries in cancer genomics with the broader oncology community.

The schedule for presentations by Foundation Medicine and/or its collaborators is as follows:

Date & Time: Saturday, June 1, 2013 from 8:00 a.m. 12:00 p.m. CT Title: Frequent LOH of CYP2D6 in ER+ breast cancer determined by next-generation sequencing (NGS) Abstract: 534 Session: Poster Discussion Session: Breast Cancer HER2/ER Location: E450b Presenter: Mark J. Ratain, M.D. Research in collaboration with The University of Chicago Comprehensive Cancer Center

Date & Time: Saturday, June 1, 2013 from 8:00 a.m. 12:00 p.m. CT Title: Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions Abstract: 10513 Session: Poster Discussion Session: Sarcoma Location: S102 Presenter: Christine M. Lovly, M.D., Ph.D. Research in collaboration with Vanderbilt-Ingram Cancer Center

Date & Time: Saturday, June 1, 2013 from 1:15 5:00 p.m. CT Title: Next generation sequencing (NGS) in patients with advanced metastatic breast cancer: identification of molecular alterations and analysis of associations with treatment on Phase I studies at MD Anderson Cancer Center Abstract: 1051 Session: General Poster Session: Breast Cancer Triple-Negative/Cytotoxics/Local Therapy Location: S Hall A2 Presenter: Jennifer J. Wheler, M.D. Research in collaboration with MD Anderson Cancer Center

Date & Time: Saturday, June 1, 2013 from 1:15 5:00 p.m. CT Title: Targeted next-generation sequencing of sarcomas for identification of therapeutic targets Abstract: 10577 Session: General Poster Session: Sarcoma Location: S Hall A2 Presenter: Vinod Ravi, M.D. Research in collaboration with MD Anderson Cancer Center

Date & Time: Saturday, June 1, 2013 from 2:00 2:15 p.m. CT Title: Next generation sequencing of genomic and cDNA identifies a high frequency of kinase fusions involving ROS1, ALK, RET, NTRK1, and BRAF in Spitz tumors Abstract: 9002 Session: Oral Abstract Session: Melanoma/Skin Cancers Location: 5406 Presenter: Boris Bastian, M.D., Ph.D., University of California, San Francisco

Date & Time: Sunday, June 2, 2013 from 8:00 8:15 a.m. CT Title: An analysis of ERBB2 alterations (amplifications and mutations) found by next generation sequencing (NGS) in 2000+ consecutive solid tumor (ST) patients Abstract: 11000 Session: Oral Abstract Session: Tumor Biology Location: E354b Presenter: Massimo Cristofanilli, M.D., F.A.C.P., Thomas Jefferson University-Kimmel Cancer Center

See the original post here:

Foundation Medicine to Present Clinical Data on its FoundationOne™ Cancer Genomic Profile at the 2013 ASCO Annual ...

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/d29n3t/personalized) has announced the addition of the "Personalized Medicine Partnering Terms and Agreements" report to their offering.

Comprehensive understanding and unprecedented access to the personalized medicine partnering deals and agreements entered into by the worlds leading healthcare companies.

The Personalized Medicine Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the personalized medicine partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter personalized medicine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors personalized medicine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

This report contains over 1500 links to online copies of actual personalized medicine deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

For more information visit http://www.researchandmarkets.com/research/d29n3t/personalized

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

The rest is here:

Research and Markets: Personalized Medicine Partnering Terms and Agreements 2013

Ancient Medicine

By: Margo Nauert

Read the rest here:

Ancient Medicine - Video

Industrial Age Medicine

By: Margo Nauert

Link:

Industrial Age Medicine - Video

Kona, Novice B, Medicine Hat, Sat May 11 2013
This was Kona #39;s 2nd Novice leg with a score of 187.5.

By: onecollie

Read more:

Kona, Novice B, Medicine Hat, Sat May 11 2013 - Video

Kid gets hit in face with medicine ball

By: wyattcheech1999

See original here:

Kid gets hit in face with medicine ball - Video

"Sound Healing and the Burgeoning Field of Harmonic Medicine" with Pamela Brady
Holistically Speaking interviews Pamela Brady about "Sound Healing and the Burgeoning Field of Harmonic Medicine"

By: Kate Lanxner

Here is the original post:

"Sound Healing and the Burgeoning Field of Harmonic Medicine" with Pamela Brady - Video

Second day... Third try... Medicine...
Carlitos has autism, and we have been trying to start this medication on a regular basis to improve speech.. But he will only take it if I record video and u...

By: Luzerito H

See original here:

Second day... Third try... Medicine... - Video

The Future of Diagnostics: Consumer Driven Medicine
What if the first step diagnosing your health was done by you, in your home, at your convenience? What if you could leverage new technology to see your ferti...

By: vlabvideos

See more here:

The Future of Diagnostics: Consumer Driven Medicine - Video

Greek Medicine Biomed
Project for Biomed Class.

By: Connor Stevenson

See the original post:

Greek Medicine Biomed - Video

Neuromics and Vitro Biopharma Expand Collaboration to Target Drug Discovery and Regenerative Medicine Markets

Golden, Colorado - Vitro Diagnostics, Inc. (VODG), dba Vitro Biopharma, announced expansion of its distribution agreement with Neuromics to include targeted sales to select markets in drug discovery & regenerative medicine. Early stages of drug development rely on in-vitro assays to identify effective new drugs and these assays are based on cellular systems. Vitro Biopharmas proprietary stem cell technology allows cost-effective manufacturing of stem cell-derived human cells and multi-cellular constructs that reflect the human in-vivo environment. We have recently developed stem cell-derived cartilage and bone producing cells called chondrocytes and osteoblasts together with various media formulations. We are now offering cells, media and custom services including genetically-engineered cells, to the biopharmaceutical industry specifically focused on drug discovery, development and toxicology for osteoporosis, Pagets disease, osteogenesis imperfecta, bone regeneration & accelerated healing of bone fractures.

This advancement allows us to now combine the distribution channels and sales/marketing expertise of Neuromics with Vitro Biopharmas proprietary technology and manufacturing to target additional markets beyond those presently being pursued in research and clinical development. In addition to markets in drug discovery, we are also pursuing select opportunities within regenerative medicine initially related to expanded use of our high performance and highly competitive MSC-Gro clinical grade media in the expansion of MSCs prior to therapeutic use. Vitro Biopharma is also developing novel stem cell-based products targeting regenerative medicine applications in animals including horses and dogs initially targeting treatment of articular injury, diseases and age-related degeneration.

Pete Shuster, the CEO of Neuromics said, Vitro Biopharmas products have performed well in the hands of our customers. We have years of experience providing primary and progenitor cells to basic and drug discovery researchers and know the importance of having best in class products and services for growing my business.

We now have the opportunity to expand into serving drug discovery for diseases that will need more cost effective treatments with our aging populations. Regenerative therapies using stem cells could prove to the silver bullet. We are working hard to everyday to make this possible

Dr Jim Musick, Vitro Biopharmas CEO, said, We are very pleased to announce our expanded relationship with Neuromics, Inc who has assisted us considerably to expand revenue generated from our products. Our new initiative is fueled by our development of stem-cell derived, differentiated cells including bone/cartilage producing osteoblasts and chondrocytes together with related media products to support use of these cellular systems in the discovery of new drugs for treatment of muscular skeletal diseases such as osteoporosis. While there are several existing drugs for use in treatment of osteoporosis there is a need for new, more effective and safer drugs especially targeting anabolic processes that promote bone generation. Our stem-cell derived human osteoblasts are ideally-suited for use in discovery of new drugs to promote osteoblast function and age-related diminished osteoblast function is a key factor in the generation of osteoporosis. Vitro Biopharma also owns proprietary technology that expands differentiation capacity of adult stem cells to pluripotent levels thus enabling us to expand our offerings of human stem cell derived cellular systems for drug discovery/development applications.

About Neuromics, Inc Neuromics (http://www.neuromics.com), located in Minneapolis, MN, is a privately-held, profitable and growing bio-reagents company. The company was initially built by supplying bio-markers to Neuroscience Researchers. Today, Neuromics provides a range of solutions that include markers, growth factors, gene expression analysis tools, apoptosis detection kits, primary cells and related media. These solutions are increasingly being used in combinations by customers to help accelerate or improve the process of drug discovery. Through the expanded association with Vitro Biopharma, the reagents offered by Neuromics for drug discovery will enhance the capabilities to serve this market sector.

About Vitro Biopharma Vitro Diagnostics, Inc. dba Vitro Biopharma (OTCQB: VODG; http://www.vitrobiopharma.com), owns US patents for production of FSH, immortalization of pituitary cells, and a cell line that produces beta islets for use in treatment of diabetes. In 2011, Vitro Biopharma out-licensed its intellectual property related to treatment of infertility to Dr. James Posillico, a renowned expert in Assisted Reproductive Technologies. Vitro Biopharma also owns a pending US patent for generation of pluripotent stem cells and an additional pending patent for methods of mesenchymal stem cell (MSC) generation and related materials. Vitro Biopharmas mission is Harnessing the Power of Cells for the advancement of regenerative medicine to its full potential. Vitro Biopharma operates within a modern biotechnology manufacturing, R&D and corporate facility in Golden, Colorado. Vitro Biopharma manufactures and sells Tools for Stem Cell and Drug Development, including human mesenchymal stem cells and derivatives, the MSC-Gro Brand of optimized media for MSC self-renewal and lineage-specific differentiation. In addition to our FSH patent licensee, Vitro Biopharma maintains several strategic partnerships including an alliance with Neuromics, Inc. (www.neuromics.com). Neuromics, Inc. is a primary distributor of Vitro Biopharma products and a well established manufacturer and distributor of a large variety of life science research products especially focused on cell-based assay systems We jointly manufacture stem cell assay systems with HemoGenix, Inc. (http://www.hemogenix.com/), known as the LUMENESC quantitative assay for determination of MSC quality, potency and response to toxic agents. Vitro Biopharma has an agreement with Stemgenesis, Inc. (http://www.stemgenesisinc.com) for distribution of its stem cell products into select Chinese provinces. Also, Vitro Biopharmas CEO is a consultant on an NSF grant at the City College of New York to advise Dr. Lane Gilcrest, Professor of Materials Science and Engineering, and his colleagues regarding the development of novel extracellular materials for use in self-renewal and differentiation of mesenchymal stem cells.

Safe Harbor Statement Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements are identified by words such as intends, anticipates, believes, expects and hopes and include, without limitation, statements regarding the Companys plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Companys products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Companys filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward looking statements, whether as a result of new information, future events or otherwise.

CONTACT: Dr. James Musick Chief Executive Officer Vitro Biopharma (303) 999-2130 Ext. 3 E-mail: jim@vitrobiopharma.com

Read more here:

Neuromics and Vitro Biopharma Expand Collaboration to Target Drug Discovery and Regenerative Medicine Markets

San Francisco, CA (PRWEB) May 14, 2013

This week Saybrook Universitys graduate School of Mind-Body Medicine signed an agreement with the San Francisco based American College of Traditional Chinese Medicine (ACTCM) to explore ways they can bring the best of 21st century western integrative health techniques to those studying traditional Chinese medicine and bring the long-held wisdom of Chinese medicine to mainstream health practitioners.

The partnership will begin with a faculty member from ACTCM developing and teaching a course at Saybrook on Whole Medical Systems that includes the principles of Traditional Chinese Medicine, and will grow to include opportunities for students at each institution to take each others courses. Both institutions anticipate whole new degree offerings coming out of this partnership.

Saybrook University, now in its 41st year, is a pioneer in distance learning. Today it combines online classes with in-person conferences and intensive seminars that give students the flexibility of online learning and the intimacy and immediacy of a classroom experience.

That means many of these new courses in traditional Chinese Medicine will be available to students anywhere in the world.

The partnership agreement was signed on May 1, and the new course offerings are expected to begin in January, 2014

The faculty and administration at ACTCM is very excited about our collaboration with Saybrook University. According to ACTCM President Lixin Huang. Our mutual commitment to integrative medicine and collaborative healthcare makes this an exciting new partnership that will bring benefits to our students, our patients and the communities we serve.

The American College of Traditional Chinese Medicine (ACTCM), founded in 1980, is at the forefront of acupuncture and Traditional Chinese Medicine education. ACTCM has two degree programsthe Master of Science in Traditional Chinese Medicine (MSTCM) and the Doctorate of Acupuncture and Oriental Medicine (DAOM). ACTCM also has an Acupuncture and Herbal Clinic, as well as acupuncture clinics in hospital and community clinic locations in the bay area, which serve as training ground for students, and provide affordable health care services for the community. ACTCM also has certificate programs in Tui Na and Shiatsu body work/medical massage as well as introductory classes for the general public.

Weve known for years that one of the areas our students are most interested in exploring is traditional Chinese medicine. Often its something their patients want to know about, too said Saybrook Provost Dan Sewell. This partnership allows us to be on the forefront of helping offer medical professionals around the country instruction of the highest caliber in this form of traditional healing. Were very excited.

Saybrooks School of Mind-Body Medicine was founded in 2009 by some of the leading practitioners of integrative health, including Dr. James Gordon, founder of the Center for Mind-Body Medicine in Washington, D.C., and Dr. Donald Moss, a past-president of the American Psychological Associations division on medical hypnosis and a board member of the Biofeedback Certification International Alliance, among other distinctions. It offers M.S. and PhD degrees in Mind-Body Medicine, including specializations in research, practice, health care systems management, and integrative mental health. It also offers Certificates in Mind-Body Medicine, Health and Wellness Coaching, Clinical Hypnosis, and Biofeedback and Neurofeedback to non-degree students.

The rest is here:

Traditional Chinese Medicine Meets American Distance Education

CHANDLER, Ariz.--(BUSINESS WIRE)--

TheNational Academy of Sports Medicine, a global leader in evidence-based certified personal training, today announcesGabby Reece, a portrait of fitness and health, is taking on her next big challenge, becoming a NASM Certified Personal Trainer.

A professional volleyball legend whose popularity and success launched careers as a sports announcer, model, actress and author, Reeces newest adventure is one that will continue to inspire her fans. She is utilizing NASMs extensive educational resources to develop a series of articles on fitness, nutrition and healthy living to share with her global following, while becoming a NASM Certified Personal Trainer. Reece will provide advice on exercise, proper diet and overall well-being, as well as blog about her journey on her highly popular website, GabbyandLaird.com, as she earns the industrys most sought-after and highly respected certification NASMs Certified Personal Trainer (CPT).

My entire career has been built on health and fitness, and I want to continue to educate myself in order to better inspire others to achieve their personal fitness goals, as well as enjoy all the benefits of healthy living, Reece said. Staying healthy and being fit is an ongoing journey, and I believe the combination of regular physical activity and proper nutrition has the power to transform lives, instill confidence and bring out the best in people.

Reece is currently studying for the CPT exam, a rigorous test that ensures proficiency in fitness assessments and training techniques, muscle groups, weight-loss measures and nutrition. The certification is considered the gold standard in the industry, reserved for the most respected certified personal trainers in the country.

Gabby Reece is anexceptionalathlete who wasinfluential toboth men and women and helped to grow the popularity of sand volleyball. But, what resonates is that she has continued to be a rolemodeloff the volleyball court. Evenaftershe stopped competing, she never let go of the idea of fitness and how it can improve one's quality of life, said Andrew Wyant, president of NASM.

For the most part, Reece will use her certification to further her personal knowledge about fitness and will share her tips on GabbyandLaird.com, a website she developed with husband and world-famous surfer Laird Hamilton. Their site gives practical advice on nutrition, fitness and self-motivation all through the lens of two experienced athletes with extensive firsthand knowledge on how to optimize the results of a fitness program. Visitors will find useful articles, suggested workouts, video tutorials, plus easily applicable tips and personal anecdotes from both Reece and Hamilton.

For more information about the NASM CPT that Reece is pursuing, visit http://www.nasm.org.

About NASM

Since 1987, the National Academy of Sports Medicine (NASM) has been a global leader in providing evidence-based certifications and advanced credentials to health and fitness professionals. In addition to its NCCA-accredited fitness Certified Personal Trainer (CPT) certification, NASM offers a progressive career track with access to Advanced Specializations including the Corrective Exercise Specialist (CES), Performance Enhancement Specialist (PES), Continuing Education courses, and accredited Bachelor and Master Degree programs. The NASM educational continuum is designed to help todays health and fitness professional enhance their career while empowering their clients to live healthier lives.

Read this article:

Volleyball Superstar, Healthy Living Expert Gabby Reece Selects National Academy of Sports Medicine

A report from the Institute of Medicine (IOM) suggests that lowering sodium below 2,300 milligrams per day may be harmful to your health.

While the organization, which is the health section of the non-profit organization the National Academy of Sciences, says that Americans are eating too much salt in their diets currently, their research has led them to conclude that lowering sodium too much may increase other adverse health risks.

"These new studies support previous findings that reducing sodium from very high intake levels to moderate levels improves health," committee chair Brian Strom, George S. Pepper Professor of Public Health and Preventive Medicine at the University of Pennsylvania Perelman School of Medicine, said in a press release. "But they also suggest that lowering sodium intake too much may actually increase a person's risk of some health problems."

Currently, the average American Adult consumes 3,400 milligrams or more of sodium a day or about 1.5 teaspoons of salt.

The current Dietary Guidelines for Americans suggests that people 14 to 50 should limit their salt intake to 2,300 milligrams daily. People 51 or older, African Americans and people with hypertension, diabetes or chronic kidney disease are recommended to keep their sodium levels below 1,500 milligrams in general. For reference, the American Heart Association (AHA) recommends that people stay below 1,500 milligrams per day to avoid heart disease and stroke risk, regardless of age, race or ethnicity.

Play Video

High levels of sodium may be linked to one-third of Americans who have high blood pressure because the extra salt retains extra fluid in the body, making the heart work harder. High salt content has also been linked to increased risk for stroke, heart failure, osteoporosis, stomach cancer and kidney disease.

While the IOM committee found that higher levels of sodium consumption increased heart disease risk, they said studies on health outcomes are inconsistent and insufficient when it comes to whether lowering salt intake to below 2,300 can decrease the risk of heart disease, stroke or all-cause mortality.

In addition, low sodium intake was shown to have negative health affects for those with mid-to-late stage heart failure. There was also not that much evidence showing the effect of low salt consumption and other subgroups, including African Americans, people over 51 and those with health conditions like diabetes, kidney disease, hypertension or borderline hypertension.

The IOM called for more research into low sodium levels between 1,500 to 2,300 milligrams per day and the various health consequences for all people.

Read the original here:

Institute of Medicine: Lowering daily sodium intake below 2,300 milligrams may do more harm than good

RUTHERFORD, N.J.--(BUSINESS WIRE)--

Cancer Genetics, Inc. (CGIX) ("CGI" or the "Company"), a leader in oncology-focused personalized medicine, will sponsor and host a roundtable discussion at the second annual BioNJ Diagnostics & Personalized Medicine Innovation Summit on Thursday, June 6, 2013 at Sanofis U.S. headquarters in Bridgewater, NJ.

The BioNJ Diagnostics & Personalized Medicine Innovation Summit will bring together leaders from major global biotechnology and pharmaceutical companies, diagnostics companies, and emerging innovator companies to discuss the latest trends, developments and challenges in the evolution and adoption of personalized medicine. The all-day event will include company presentations, networking opportunities, and moderated panel discussions focused on research and commercialization challenges in diagnostics and personalized medicine.

Panna Sharma, CEO and President of CGI, will moderate a morning roundtable discussion that will offer a cross-industry perspective from thought leaders and operators in the frontline of driving personalized medicine. The panel will discuss trends and strategies that are emerging among leading companies in personalized medicine. Panelists include:

To learn more about the BioNJ Diagnostics & Personalized Medicine Innovation Summit, visit http://www.bionj.org/diagnostics-and-personalized-medicine-innovation-summit.

About Cancer Genetics, Inc.

Cancer Genetics, Inc. (CGI) is an emerging leader in DNA-based cancer diagnostics and servicessome of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also provide a comprehensive range of non-proprietary oncology-focused tests and laboratory services.

CGIs cutting-edge proprietary tests and state-of-the-art reference laboratory provide critical genomic information to healthcare professionals as well as biopharma and biotech. Our state-of-the-art reference lab is focused entirely on maintaining clinical excellence and is both CLIA certified and CAP accredited and has licensure from several states including New York State.

Founded in 1999 by world-renowned cytogeneticist Dr. R.S.K. Chaganti, the Company has been built on a foundation of world-class scientific knowledge and IP in solid and blood-borne cancers, and has established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic and the National Cancer Institute. For further information, please seewww.cancergenetics.com.

Continued here:

Cancer Genetics to Sponsor and Host Roundtable at BioNJ Diagnostics & Personalized Medicine Innovation Summit